Plainsboro, New Jersey Monday, May 5, 2025, 14:00 Hrs [IST] ...

Nationally representative survey data reveals that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity treatment more than tripled among US adults without diabetes between 2018 and ...

Currently, more than 42% of adults in the United States have obesity. Among young people, about 1 in 5 adolescents are also ...

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

A decision is expected in the fourth quarter of 2025.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Obesity and poor diet quality are major issues among adults with severe mental illness, and current weight management ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity epidemic, according to Reuters.

Adults who developed severe obesity before the age of 18 are nearly three times more likely than those who developed the ...